The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
Open accessAbstract
Immune checkpoint blockade (ICB) has demonstrated curative potential in several types of cancer, but only for a small number of patients. Thus, the identification of reliable and noninvasive biomarkers for predicting ICB responsiveness is an urgent unmet need. Here, we show that ICB increased tumor vessel perfusion in treatment-sensitive EO771 and MMTV-PyVT breast tumor as well as CT26 and MCA38 colon tumor models, but not in treatment-resistant MCaP0008 and 4T1 breast tumor models. In the sensitive tumor models, the ability of anti-cytotoxic T lymphocyte-associated protein 4 or anti-programmed cell death 1 therapy to increase vessel perfusion strongly correlated with its antitumor efficacy. Moreover, globally enhanced tumor vessel perfusion could be detected by Doppler ultrasonography before changes in tumor size, which predicted final therapeutic efficacy with more than 90% sensitivity and specificity. Mechanistically, CD8+ T cell depletion, IFN-γ neutralization, or implantation of tumors in IFN-γ receptor knockout mice abrogated the vessel perfusion enhancement and antitumor effects of ICB. These results demonstrated that ICB increased vessel perfusion by promoting CD8+ T cell accumulation and IFN-γ production, indicating that increased vessel perfusion reflects the successful activation of antitumor T cell immunity by ICB. Our findings suggest that vessel perfusion can be used as a novel noninvasive indicator for predicting ICB responsiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An improved vascular network favors adaptive antitumor immunity by promoting trafficking and re-localization of tumor-infiltrating lymphocytes (TILs), leading to improved outcomes of various immunotherapies, including immune checkpoint blockade (ICB) (15-20).”
In the citing paper
“We previously demonstrated that vascular normalization could increase immune cells’ infiltration into tumors, and multiple studies have confirmed these findings in several tumor models (15,17-19).”
In the citing paper
“Lack of perfusion, tumoral hypoxia, and T-cell exclusion are considered significant resistance mechanisms (15,17-19).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Tumor vascular normalization refers to a process in which the tumor vasculature is remodeled to more closely resemble that of normal tissue vessels, and increased vessel perfusion (IVP) is a critical component of this process (20, 24, 25).”
BackgroundThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Cited by
Sorted by citations
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 736
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 691
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 621
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Shigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, É., Aoki, S., Ramjiawan, R. R., et al. (2019) · Hepatology · doi:10.1002/hep.30889 · Cited by 415
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
Pinter, M., Jain, R. K., & Duda, D. G. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 352
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 320
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Combining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 297
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 273
Hypoxia as a driver of resistance to immunotherapy
Kopecka, J., Salaroglio, I. C., Pérez-Ruiz, E., Sarmento‐Ribeiro, A. B., Saponara, S., Rivas, J. D. L., & Riganti, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100787 · Cited by 264
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Vascular regulation of antitumor immunity
Munn, L. L., & Jain, R. K. (2019) · Science · doi:10.1126/science.aaw7875 · Cited by 194
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 204
Donlon, N., Power, R. F., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 199
Gomes-Santos, I. L., Amoozgar, Z., Kumar, A. S., Ho, W. W., Roh, K., Talele, N. P., Curtis, H., Kawaguchi, K., Jain, R. K., & Fukumura, D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0499 · Cited by 181
The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Y., Liu, Z.-G., Yuan, H., Deng, W., Li, J., Huang, Y.-H., Kim, B. Y. S., Story, M. D., & Jiang, W. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2581 · Cited by 184
Self-citationTumor microenvironment and radioresistance
Suwa, T., Kobayashi, M., Nam, J., & Harada, H. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00640-9 · Cited by 186
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Xing, R., Gao, J., Cui, Q., & Wang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783236 · Cited by 172
Ding, H., Wang, G., Yu, Z., Sun, H., & Wang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113683 · Cited by 163
Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 156
Self-citationMa, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143
Zhang, D., Li, A. M., Hu, G., Huang, M., Yang, F., Zhang, L., Wellen, K. E., Xu, X., Conn, C. S., Zou, W., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.010 · Cited by 141
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 140
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 122
Self-citationVascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 126
Self-citationLv, H., Zong, Q., Chen, C., Lv, G., Xiang, W., Xing, F., Jiang, G., Yan, B., Sun, X., Ma, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43743-9 · Cited by 117
Zhou, H., Wang, M., Zhang, Y., Su, Q., Xie, Z., Chen, X., Yan, R., Li, P., Li, T., Qin, X., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12294 · Cited by 115
Self-citationCoagulome and the tumor microenvironment: an actionable interplay
Galmiche, A., Rak, J., Roumenina, L. T., & Saidak, Z. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.008 · Cited by 111
Bacteria-derived membrane vesicles to advance targeted photothermal tumor ablation
Zhuang, Q., Xu, J., Deng, D., Chao, T., Li, J., Zhang, R., Peng, R., & Liu, Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120550 · Cited by 109
Mpekris, F., Panagi, M., Voutouri, C., Martin, J. D., Samuel, R., Takahashi, S., Gotohda, N., Suzuki, T., Papageorgis, P., Demetriou, P., et al. (2020) · Advanced Science · doi:10.1002/advs.202001917 · Cited by 104
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 102
Alleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 101
Self-citationKurebayashi, Y., Matsuda, K., Ueno, A., Tsujikawa, H., Yamazaki, K., Masugi, Y., Kwa, W. T., Effendi, K., Hasegawa, Y., Yagi, H., et al. (2021) · Hepatology · doi:10.1002/hep.32201 · Cited by 101
Wu, S., Xu, Y., Chen, L., Fan, L., Ma, X.-Y., Zhao, S., Song, X.-Q., Hu, X., Yang, W.-T., Chai, W.-J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01536-6 · Cited by 97
Self-citationCancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 93
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Yang, M., Cui, M., Sun, Y., Liu, S., & Jiang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01711-w · Cited by 102
Self-citationQian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291530 · Cited by 99
Li, N., Tang, J., Yang, J., Zhu, B., Wang, X., Luo, Y., Yang, H., Jang, F., Zou, J., Liu, Z., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.046 · Cited by 88
Self-citationMahaki, H., Nobari, S., Tanzadehpanah, H., Babaeizad, A., Kazemzadeh, G., Mehrabzadeh, M., Valipour, A., Yazdinezhad, N., Manoochehri, H., Yang, P., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118023 · Cited by 100
Liu, Y., Zhang, M., Wang, X., Yang, F., Cao, Z., Wang, L., & Liu, J. (2022) · Advanced Materials · doi:10.1002/adma.202210949 · Cited by 85
Self-citationLi, S., Chen, J. Y., & Sun, Z. (2021) · 癌症：英文版 · doi:10.1002/cac2.12183 · Cited by 79
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment
Zhao, Y., Yu, X., & Li, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.014 · Cited by 81
Self-citationEO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty
Naour, A. L., Rossary, A., & Vasson, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3295 · Cited by 77
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
Lu, L., Zhan, M., Li, X.-Y., Zhang, H., Dauphars, D. J., Jiang, J., Yin, H., Li, S., Luo, S., Li, Y., et al. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.05.003 · Cited by 77
Cortellino, S., Raveane, A., Chiodoni, C., Delfanti, G., Pisati, F., Spagnolo, V., Visco, E., Fragale, G., Ferrante, F., Magni, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111256 · Cited by 76
Combination of Fruquintinib and Anti–PD-1 for the Treatment of Colorectal Cancer
Wang, Y., Wei, B., Gao, J., Cai, X., Xu, L., Zhong, H., Wang, B., Sun, Y., Guo, W., Xu, Q., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000463 · Cited by 73
Stein, J. E., Soni, A., Danilova, L., Cottrell, T. R., Gajewski, T. F., Hodi, F. S., Bhatia, S., Urba, W. J., Sharfman, W. H., Wind‐Rotolo, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz019 · Cited by 73
Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 78
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 77
Milestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 79
CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 76
Self-citationTumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
Lanitis, E., Irving, M. B., & Coukos, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01187-w · Cited by 81
Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner
Deng, S., Zhang, G., Kuai, J., Fan, P., Wang, X., Zhou, P., Yang, D., Zheng, X., Liu, X., Wu, Q., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0932-y · Cited by 74
Self-citationKikuchi, H., Matsui, A., Morita, S., Amoozgar, Z., Inoue, K., Ruan, Z., Staiculescu, D., Wong, J. S. L., Huang, P., Yau, T. C. C., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac051 · Cited by 67
Organoid models of glioblastoma: advances, applications and challenges.
Zhang, C., Jin, M.-Z., Zhao, J., Chen, J., & Jin, W. (2020) · PubMed Central · Cited by 66
Self-citationTherapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling
Johansson, A., & Ganß, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674375 · Cited by 65
Recent advances of nanotechnology-based tumor vessel-targeting strategies
Zhu, D., Li, Y., Zhang, Z., Xue, Z., Hua, Z., Luo, X., Zhao, T., Lu, C. C., & Liu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01190-y · Cited by 59
Chen, I. X., Newcomer, K., Pauken, K. E., Juneja, V. R., Naxerova, K., Wu, M. W., Pinter, M., Sen, D. R., Singer, M., Sharpe, A. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002806117 · Cited by 55
Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 54
Self-citationReeves, K. M., Song, P. N., Angermeier, A., Manna, D. D., Li, Y., Wang, J., Yang, E. S.-H., Sorace, A. G., & Larimer, B. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2394 · Cited by 56
Okuyama, K., Naruse, T., & Yanamoto, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02691-4 · Cited by 55
Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade
Miyai, Y., Sugiyama, D., Hase, T., Asai, N., Taki, T., Nishida, K., Fukui, T., Chen-Yoshikawa, T. F., Kobayashi, H., Mii, S., et al. (2022) · Life Science Alliance · doi:10.26508/lsa.202101230 · Cited by 55
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
Mpekris, F., Panagi, M., Charalambous, A., Voutouri, C., & Stylianopoulos, T. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101626 · Cited by 55
Ultrasound stiffness and perfusion markers correlate with tumor volume responses to immunotherapy
Voutouri, C., Mpekris, F., Panagi, M., Krolak, C., Michael, C., Martin, J. D., Averkiou, M. A., & Stylianopoulos, T. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.007 · Cited by 49
DLL1 orchestrates CD8 + T cells to induce long-term vascular normalization and tumor regression
Zhang, N., Yin, R., Zhou, P., Liu, X., Fan, P., Qian, L., Li, D., Zhang, C., Zheng, X., Deng, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020057118 · Cited by 50
Self-citationZheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 50
Self-citationZhang, B., Wang, C., Wu, H., Wang, F., Chai, Y., Hu, Y., Wang, B., Zhou, Y. L., Xia, R., Xu, R., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12476 · Cited by 47
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
Li, S., Zhang, Q., & Hong, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980116 · Cited by 52
Fan, P., Qiang, H., Liu, Z., Zhao, Q., Wang, Y., Liu, T., Wang, X., Chu, T., Huang, Y., Xu, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937924 · Cited by 41
Self-citationAnti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
Li, A., & Fang, J. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230025 · Cited by 46
Jancewicz, I., Szarkowska, J., Konopiński, R., Stachowiak, M., Swiatek, M., Błachnio, K., Kubala, S., Oksinska, P., Cwiek, P., Rusetska, N., et al. (2021) · Cancers · doi:10.3390/cancers13164148 · Cited by 42
Panagi, M., Mpekris, F., Voutouri, C., Hadjigeorgiou, A. G., Symeonidou, C., Porfyriou, E., Michael, C., Stylianou, A., Martin, J. D., Cabral, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0246 · Cited by 47
Zhu, L., Yu, X., Wang, L., Liu, J., Qu, Z., Zhang, H., Li, L., Chen, J., & Zhou, Q. (2021) · Oncogenesis · doi:10.1038/s41389-021-00335-w · Cited by 45
Emerging nanotechnological approaches to regulating tumor vasculature for cancer therapy
Wang, C., Xu, J., Zhang, Y., & Nie, G. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.017 · Cited by 40
Choi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 40
Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy
Xuan, L., Bai, C., Ju, Z., Luo, J., Guan, H., Zhou, P., & Huang, R. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.003 · Cited by 42
Self-citationMyeloid effector cells in cancer
Schol, P. J., van Elsas, M. J., Middelburg, J., Twilhaar, M. K. N., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.002 · Cited by 39
Voutouri, C., Panagi, M., Mpekris, F., Stylianou, A., Michael, C., Averkiou, M. A., Martin, J. D., & Stylianopoulos, T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000289 · Cited by 38
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 37
Self-citationKurebayashi, Y., Olkowski, C. P., Lane, K. C., Vasalatiy, O. V., Xu, B., Okada, R., Furusawa, A., Choyke, P. L., Kobayashi, H., & Sato, N. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2673 · Cited by 38
The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma
Ghosh, M., Lenkiewicz, A. M., & Kaminska, B. (2022) · Biomedicines · doi:10.3390/biomedicines10092292 · Cited by 37
Tumour vessel remodelling: new opportunities in cancer treatment
Ganß, R. (2020) · Vascular Biology · doi:10.1530/vb-19-0032 · Cited by 39
Gao, Z., Zhao, Q., Xu, Y., & Wang, L. (2023) · Radiation Oncology · doi:10.1186/s13014-023-02278-5 · Cited by 34
Li, S., Yang, Y., & Ye, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i42.6034 · Cited by 35
Hill, R. M., Rocha, S., & Parsons, J. L. (2022) · Cancers · doi:10.3390/cancers14174130 · Cited by 33
Tumor endothelial cell autophagy is a key vascular‐immune checkpoint in melanoma
Verhoeven, J., Jacobs, K., Rizzollo, F., Lodi, F., Hua, Y., Poźniak, J., Srinivasan, A. N., Houbaert, D., Shankar, G., More, S., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202318028 · Cited by 35
Portillo, A. L., Monteiro, J. K., Rojas, E. A. P., Ritchie, T. M., Gillgrass, A. E., & Ashkar, A. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286750 · Cited by 32
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking
Zhao, Y., Ting, K. K., Coleman, P. R., Qi, Y., Chen, J., Vadas, M. A., & Gamble, J. R. (2021) · Cancers · doi:10.3390/cancers13071724 · Cited by 34
Self-citationPark, S., Oh, J. H., Park, D. J., Zhang, H., Noh, M., Kim, Y., Kim, Y.-S., Kim, H., Kim, Y., Ha, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620166 · Cited by 30
Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
Shi, L. Z., & Bonner, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212295 · Cited by 28
Tao, D., Wang, Y., Zhang, X., Wang, C., Yang, D., Chen, J., Long, Y., Jiang, Y., Zhou, X., & Zhang, N. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.853324 · Cited by 29
Shafqat, A., Omer, M. H., Ahmed, E. N., Mushtaq, A. H., Ijaz, E., Ahmed, Z., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200941 · Cited by 32
Pericytes: jack-of-all-trades in cancer-related inflammation
Moro, M., Balestrero, F. C., & Grolla, A. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1426033 · Cited by 30
Kim, Y.-M., Sanborn, M. A., Vijeth, S., Gajwani, P., Wang, X., Jung, D., Vályi-Nagy, T., Chakraborty, S., Mancinelli, G. E., Tóth, P. T., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00975-6 · Cited by 28
Self-citationZhou, Y. J., Liu, Z., Yu, A., Zhao, G., & Chen, B. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s494670 · Cited by 30
Modulation of the Vascular-Immune Environment in Metastatic Cancer
He, B., & Ganß, R. (2021) · Cancers · doi:10.3390/cancers13040810 · Cited by 26
Effects of exercise and anti-PD-1 on the tumour microenvironment
Buss, L. A., Williams, T., Hock, B. D., Ang, A. D., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.08.005 · Cited by 26
Current advances in modulating tumor hypoxia for enhanced therapeutic efficacy
Liu, Z., Liu, X., Zhang, W., Gao, R., Wei, H., & Yu, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.010 · Cited by 26
Self-citation
Metadata
- Authors
- Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., Han, Y., Zhao, Y., Lin, S. H., Qin, S., Wang, X., Kim, B. Y. S., Zhou, P., Jiang, W., Wu, Q., & Huang, Y.
- Affiliations
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Soochow University (CN)
- Soochow University (CN)
- Chinese Academy of Sciences (CN)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic in Florida (US)
- Corresponding author
- Huang, Yuhui
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-04-16
- Volume
- 128
- Issue
- 5
- Pages
- 2104-2115
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5957454
- OpenAlex
- W2800799386
- Cited by
- 239
- References
- 48
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 47 · 2022: 33 · 2021: 31 · 2020: 28 · 2019: 9 · 2018: 5
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- the National Natural Science Foundation of China (81372245, 81673004)
- the National Program on Key Research Project of China (2016YFC1302400)
- the National Institute of Neurological Disorders and Stroke (R01 NS104315)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- immune checkpoint blockade, predictive biomarkers, CTLA-4, PD-1, CD8+ T cells, interferon-gamma, T cell-mediated antitumor immunity, Doppler ultrasound, breast cancer, colon cancer, treatment resistance, tumor microvasculature
- MeSH terms
- Animals, Colonic Neoplasms, Interferon-gamma, Lymphocyte Depletion, Mammary Neoplasms, Experimental, Perfusion, CD8-Positive T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
